

# Lifevantage Corp. (LFVN)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000849146

| Lifevantage Corp.    |                                                                                                                                    |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------|
| LFVN; healthcare     |                                                                                                                                    |
| Grade                | <p><b>B/C</b></p> <p>on the B/C boundary of 371 graded peers<br/>percentile 41.1; sampling error 2.5 points; lower is stronger</p> |
| Rank                 | 153 of 371                                                                                                                         |
| Profitability        | <p>B</p> <p>percentile 24.1</p>                                                                                                    |
| Solvency             | <p>C/D</p> <p>percentile 58.5</p>                                                                                                  |
| Growth and financing | <p>C</p> <p>percentile 55.4</p>                                                                                                    |
| Reliability          | <p>0.83 AUC</p> <p>filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025</p>                   |
| Peer failure rate    | <p>1.07% a year</p> <p>Item 1.03 bankruptcies, same asset band, 2012 to 2025</p>                                                   |
| Size band            | <p>\$12.5M to \$120M assets</p> <p>total assets \$62.1M</p>                                                                        |
| Standard universe    | <p>inside</p> <p>revenue above \$1M and assets above \$10M</p>                                                                     |
| Warnings             | <p>none active</p> <p>not computable: short runway, distress, fortress balance sheet</p>                                           |
| Inputs computable    | 10 of 14                                                                                                                           |
| Graded from          | <p>filings received through Aug 27, 2026</p> <p>43 days before the rescan; latest periodic filing 10-K received Aug 27, 2026</p>   |
| Last close           | <p>\$5.99</p> <p>2026-10-08; market equity \$75.0M</p>                                                                             |
| Price used in grade  | None                                                                                                                               |

## Letter at every rescans

*Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only*



## Business, in the company's words

opening of Item 1 of the 10-K received Aug 27, 2026

LifeVantage Corporation (the "Company," "LifeVantage," "we," "us," or "our") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. LifeVantage is dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and

independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants.


## The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

| Input                                               | Percentile, 0 to 100                                                                | Value          | Peer median | Percentile | Peers | Period end                                                                                 |
|-----------------------------------------------------|-------------------------------------------------------------------------------------|----------------|-------------|------------|-------|--------------------------------------------------------------------------------------------|
| <b>Profitability, sleeve percentile 24.1</b>        |                                                                                     |                |             |            |       |                                                                                            |
| Gross profitability                                 |    | 228.0%         | 32.2%       | 0.8        | 372   | 2026-06-30                                                                                 |
| Return on invested capital                          |                                                                                     | not computable | 9.3%        |            |       | one or more required annual facts are missing                                              |
| Accruals ratio                                      |    | (7.7%)         | (6.6%)      | 51.2       | 811   | 2026-06-30                                                                                 |
| Gross margin stability, five years                  |    | 1.3 pts        | 2.8 pts     | 20.2       | 243   | 2026-06-30                                                                                 |
| <b>Solvency, sleeve percentile 58.5</b>             |                                                                                     |                |             |            |       |                                                                                            |
| Twelve-month failure probability                    |                                                                                     | not computable | 0.07%       |            |       | latest liabilities, cash plus short-term investments, book equity, and shares are required |
| Altman Z double-prime                               |    | (1.63)         | (0.31)      | 43.7       | 756   | 2026-06-30                                                                                 |
| Net debt to EBITDA                                  |                                                                                     | not computable | 1.82x       |            |       | one or more required annual facts are missing                                              |
| Interest coverage                                   |                                                                                     | not computable | (4.51x)     |            |       | latest aligned inputs end 2024-06-30; latest annual assets end 2026-06-30                  |
| Current ratio                                       |  | 1.89x          | 2.96x       | 73.3       | 839   | 2026-06-30                                                                                 |
| <b>Growth and financing, sleeve percentile 55.4</b> |                                                                                     |                |             |            |       |                                                                                            |
| Revenue growth, three-year compound                 |  | (5.1%)         | 10.0%       | 80.0       | 415   | 2026-06-30                                                                                 |
| Free cash flow growth, three-year compound          |  | 21.0%          | 10.9%       | 42.1       | 96    | 2026-06-30                                                                                 |
| Reinvestment rate                                   |  | (94.3%)        | 37.1%       | 90.3       | 104   | 2026-06-30                                                                                 |
| Asset growth, three years                           |  | (2.1%)         | 2.1%        | 56.5       | 704   | 2026-06-30                                                                                 |
| Net share issuance, one year                        |  | (1.3%)         | 2.5%        | 8.2        | 634   | 2026-08-26                                                                                 |

## Among 371 peers

healthcare; letters are fifths of this list



| Rank | Company                           | Percentile | Letter | Warnings     |
|------|-----------------------------------|------------|--------|--------------|
| 148  | Celldex Therapeutics, Inc. (CLDX) | 39.7       | B/C    | short runway |

|     |                                       |      |     |                                          |
|-----|---------------------------------------|------|-----|------------------------------------------|
| 149 | National Healthcare Corp. (NHC)       | 40.0 | B/C | fortress<br>balance sheet                |
| 150 | ImmunityBio, Inc. (IBRX)              | 40.3 | B/C | short runway                             |
| 151 | Shattuck Labs, Inc. (STTK)            | 40.5 | B/C | dilution                                 |
| 152 | Myomo, Inc. (MYO)                     | 40.8 | B/C | fortress<br>balance sheet                |
| 153 | Lifevantage Corp. (LFVN) <            | 41.1 | B/C |                                          |
| 154 | Repligen Corp. (RGEN)                 | 41.4 | B/C | late filer,<br>fortress<br>balance sheet |
| 155 | Envista Holdings Corp. (NVST)         | 41.6 | B/C |                                          |
| 156 | Xeris Biopharma Holdings, Inc. (XERS) | 41.9 | B/C |                                          |
| 157 | Sight Sciences, Inc. (SGHT)           | 42.2 | B/C | fortress<br>balance sheet                |
| 158 | Community Health Systems Inc. (CYH)   | 42.4 | B/C |                                          |

## What the price implies

at the 2026-10-08 close; none enters the grade

| Measure                                                 | Value   | Peer median | Percentile |
|---------------------------------------------------------|---------|-------------|------------|
| Twelve-month price change, skipping the latest month    | (34.0%) | 8.0%        | 21         |
| Distance from 52-week high                              | (44.0%) | (31.4%)     | 34         |
| EBIT to enterprise value                                | 6.4%    | (1.5%)      | 83         |
| Free cash flow yield                                    | 8.9%    | (1.0%)      | 89         |
| Book value to price                                     | 0.45    | 0.28        | 66         |
| Sales to price                                          | 2.43    | 0.31        | 93         |
| Composite equity issuance, five years                   | (23.9%) | 20.3%       | 5          |
| Relative strength against the sector, log excess return | (0.63)  | (0.14)      | 21         |

## Diagnostics

not in the grade

| Measure                                                   | Value                           |
|-----------------------------------------------------------|---------------------------------|
| <b>Piotroski F-score None of 9, period end 2026-06-30</b> |                                 |
| Return on assets above zero                               | pass                            |
| Operating cash flow above zero                            | pass                            |
| Return on assets improved                                 | fail                            |
| Operating cash flow exceeds net income                    | pass                            |
| Long-term leverage fell                                   | fail                            |
| Current ratio improved                                    | pass                            |
| No new shares issued                                      | pass                            |
| Gross margin improved                                     | fail                            |
| Asset turnover improved                                   | fail                            |
| <b>Cash, filings, liquidity</b>                           |                                 |
| Cash and equivalents                                      | n/a                             |
| Operating cash flow, four quarters                        | n/a                             |
| Months of runway                                          | not finite                      |
| Days since last periodic filing                           | 43 (10-K received Aug 27, 2026) |
| Median daily dollar volume, 63 sessions                   | \$324,104                       |

## Sources

each row links to the filing index on sec.gov

| # | Concept             | XBRL tag                                                    | Value    | Period end | Received   | Form | Accession            |
|---|---------------------|-------------------------------------------------------------|----------|------------|------------|------|----------------------|
| 1 | gross profit        | us-gaap:GrossProfit                                         | \$141.6M | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 2 | assets              | us-gaap:Assets                                              | \$62.1M  | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 3 | net income          | us-gaap:NetIncomeLoss                                       | \$5.1M   | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities          | \$10.2M  | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 5 | assets              | us-gaap:Assets                                              | \$72.0M  | 2025-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 6 | revenue             | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$182.6M | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |

|    |                           |                                                                                              |            |            |            |      |                      |
|----|---------------------------|----------------------------------------------------------------------------------------------|------------|------------|------------|------|----------------------|
| 7  | gross profit              | us-gaap:GrossProfit                                                                          | \$183.7M   | 2025-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 8  | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                                  | \$228.5M   | 2025-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 9  | gross profit              | us-gaap:GrossProfit                                                                          | \$158.7M   | 2024-06-30 | 2025-09-04 | 10-K | 0000849146-25-000068 |
| 10 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                                  | \$200.2M   | 2024-06-30 | 2025-09-04 | 10-K | 0000849146-25-000068 |
| 11 | gross profit              | us-gaap:GrossProfit                                                                          | \$170.0M   | 2023-06-30 | 2024-08-28 | 10-K | 0000849146-24-000073 |
| 12 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                                  | \$213.4M   | 2023-06-30 | 2024-08-28 | 10-K | 0000849146-24-000073 |
| 13 | gross profit              | us-gaap:GrossProfit                                                                          | \$168.3M   | 2022-06-30 | 2023-08-28 | 10-K | 0000849146-23-000102 |
| 14 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                                  | \$206.4M   | 2022-06-30 | 2023-08-28 | 10-K | 0000849146-23-000102 |
| 15 | current assets            | us-gaap:AssetsCurrent                                                                        | \$38.3M    | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 16 | current liabilities       | us-gaap:LiabilitiesCurrent                                                                   | \$20.2M    | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 17 | retained earnings         | us-gaap:RetainedEarningsAccumulatedDeficit                                                   | -\$103.5M  | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 18 | operating income          | us-gaap:OperatingIncomeLoss                                                                  | \$6.1M     | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 19 | book equity               | us-gaap:StockholdersEquity                                                                   | \$33.6M    | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 20 | liabilities               | us-gaap:Liabilities                                                                          | \$28.5M    | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 21 | operating income          | us-gaap:OperatingIncomeLoss                                                                  | \$4.3M     | 2024-06-30 | 2025-09-04 | 10-K | 0000849146-25-000068 |
| 22 | interest expense          | us-gaap:InterestExpense                                                                      | -\$430,000 | 2024-06-30 | 2024-08-28 | 10-K | 0000849146-24-000073 |
| 23 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment                                           | \$3.6M     | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 24 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities                                           | \$11.9M    | 2025-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 25 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment                                           | \$1.4M     | 2025-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 26 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities                                           | \$12.2M    | 2024-06-30 | 2025-09-04 | 10-K | 0000849146-25-000068 |
| 27 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment                                           | \$2.2M     | 2024-06-30 | 2025-09-04 | 10-K | 0000849146-25-000068 |
| 28 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities                                           | \$6.8M     | 2023-06-30 | 2024-08-28 | 10-K | 0000849146-24-000073 |
| 29 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment                                           | \$3.1M     | 2023-06-30 | 2024-08-28 | 10-K | 0000849146-24-000073 |
| 30 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization                                                 | \$2.8M     | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 31 | pretax income             | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems | \$6.1M     | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 32 | income tax                | us-gaap:IncomeTaxExpenseBenefit                                                              | \$994,000  | 2026-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 33 | current assets            | us-gaap:AssetsCurrent                                                                        | \$50.9M    | 2025-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 34 | current liabilities       | us-gaap:LiabilitiesCurrent                                                                   | \$27.2M    | 2025-06-30 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 35 | assets                    | us-gaap:Assets                                                                               | \$60.3M    | 2024-06-30 | 2025-09-04 | 10-K | 0000849146-25-000068 |
| 36 | assets                    | us-gaap:Assets                                                                               | \$66.1M    | 2023-06-30 | 2024-08-28 | 10-K | 0000849146-24-000073 |
| 37 | shares outstanding        | dei:EntityCommonStockSharesOutstanding                                                       | 12,527,348 | 2026-08-26 | 2026-08-27 | 10-K | 0001193125-26-371257 |
| 38 | shares outstanding        | dei:EntityCommonStockSharesOutstanding                                                       | 12,691,009 | 2025-09-03 | 2025-09-04 | 10-K | 0000849146-25-000068 |